209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein

P.Sch?ffski; I.Breidenbach; O.Bolte; M.Stadler; S.Zilz; K.Wilhelm-Ogunbiyi; H.Lentzen

首页> 外文期刊>European Journal of Cancer Supplements >209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein

【24h】

209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein

机译：209难治性实体瘤患者的I期临床试验：每周24小时静脉输注阿维斯卡汀（一种重组核糖体失活蛋白）

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2004年第8期|共2页
作者
P.Sch?ffski; I.Breidenbach; O.Bolte; M.Stadler; S.Zilz; K.Wilhelm-Ogunbiyi; H.Lentzen;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. [J] . Tabernero J, Rojo F, Marimon I, Journal of Clinical Oncology . 2005,第11期

机译：晚期实体瘤患者每周一次1小时和24小时输注BMS-214662（一种法尼基转移酶抑制剂）的I期药代动力学和药效学研究。
2. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. [J] . Maroun JA, Belanger K, Seymour L, Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第9期

机译：对于标准疗法难治的实体瘤患者，每3周每天x5 1小时输注Aplidine的I期研究。加拿大国家癌症研究所临床试验小组的研究：NCIC CTG IND 115。
3. Phase I study of Aplidine in a daily×5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115 [J] . JA Maroun, K Belanger, L Seymour, Annals of Oncology . 2006,第9期

机译：对标准疗法难治的实体瘤患者，每3周每天进行一次×5每小时一小时的阿普立定I期研究。加拿大国家癌症研究所临床试验小组的研究：NCIC CTG IND 115
4. Phase I Clinical Trial with Her-2 B-Cell Chimeric and MultiEpitope Based Peptide Vaccines in Patients with Metastatic and/or Recurrent Solid Tumors [C] . Pravin T.P. Kaumaya, Kevin Chu Foy, Joan Garrett American Peptide Symposium . 2009

机译：患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A Phase I Trial and Pharmacokinetic Study of a 24-hour Infusion of Trabectedin (Yondelis® ET-743) in Children and Adolescents with Relapsed or Refractory Solid Tumors [O] . Meredith K. Chuk, Alberta Aikin, Trish Whitcomb, -1

机译：在具有复发或难证的固体肿瘤的儿童和青少年中24小时输注Treabledin（Yondelis®et-743）的24小时试验和药代动力学研究
7. Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors [O] . Miguel A. Izquierdo, Angela Bowman, Margarita García, 2008

机译：Plitidepsin的I期临床和药代动力学研究作为晚期实体肿瘤患者每周一次静脉内输注

209 Phase I clinical trial in patients with refractory solid tumors: the weekly 24 hour intravenous infusion of aviscumine, a recombinant ribosome-inactivating protein

著录项

引文网络

相似文献

相关主题

期刊订阅